Literature DB >> 10437790

Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases.

G Kostoulas1, A Lang, H Nagase, A Baici.   

Abstract

The tissue inhibitors of matrix metalloproteinases (MMPs), TIMP-1 and TIMP-2, are also angiogenesis inhibitors. Cathepsin B and MMPs are found at sites of neovascularization in pathologies such as cancer and osteoarthritis. Treatment of TIMP-1, TIMP-2, and of a mixture of both inhibitors from human articular chondrocytes with cathepsin B resulted in their fragmentation, whereby they lost their MMP-inhibitory and anti-angiogenic activities. Our data suggest that, besides directly participating in tissue destruction, cathepsin B can be harmful for two further reasons: it raises the activity of the MMPs also in the absence of mechanisms up-regulating these enzymes, and it stimulates angiogenesis. This is a prerequisite for blood vessel invasion in a variety of pathological situations of which cancer and osteoarthritis are prominent examples.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10437790     DOI: 10.1016/s0014-5793(99)00897-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  36 in total

1.  Modulation of endothelial cell morphogenesis in vitro by MMP-9 during glial-endothelial cell interactions.

Authors:  N Chandrasekar; S Jasti; W K Alfred-Yung; F Ali-Osman; D H Dinh; W C Olivero; M Gujrati; A P Kyritsis; G L Nicolson; J S Rao; S Mohanam
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Targeting Cathepsin B for Cancer Therapies.

Authors:  Hang Ruan; Susan Hao; Peter Young; Hongtao Zhang
Journal:  Horiz Cancer Res       Date:  2015 2nd Quarter

3.  Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas.

Authors:  Maode Wang; Jianjian Tang; Shouxun Liu; Daizo Yoshida; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  Systemic administration of ribbon-type decoy oligodeoxynucleotide against nuclear factor κB and ets prevents abdominal aortic aneurysm in rat model.

Authors:  Takashi Miyake; Motokuni Aoki; Mariana K Osako; Munehisa Shimamura; Hironori Nakagami; Ryuichi Morishita
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

Review 5.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

6.  Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Andrzej Wincewicz; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

7.  Crystal structure of NS-134 in complex with bovine cathepsin B: a two-headed epoxysuccinyl inhibitor extends along the entire active-site cleft.

Authors:  Igor Stern; Norbert Schaschke; Luis Moroder; Dusan Turk
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

8.  Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides.

Authors:  Maria Helena S Cezari; Luciano Puzer; Maria Aparecida Juliano; Adriana K Carmona; Luiz Juliano
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

Review 9.  Optimizing dentin bond durability: control of collagen degradation by matrix metalloproteinases and cysteine cathepsins.

Authors:  Leo Tjäderhane; Fabio D Nascimento; Lorenzo Breschi; Annalisa Mazzoni; Ivarne L S Tersariol; Saulo Geraldeli; Arzu Tezvergil-Mutluay; Marcela R Carrilho; Ricardo M Carvalho; Franklin R Tay; David H Pashley
Journal:  Dent Mater       Date:  2012-08-16       Impact factor: 5.304

Review 10.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response.

Authors:  Oakley C Olson; Johanna A Joyce
Journal:  Nat Rev Cancer       Date:  2015-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.